ASCO 2017 Prostate Cancer - Results from #42

Viewing 43-62 of 85 articles

ASCO 2017: Predictors of post-surgical race-specific prostate cancer progression

ASCO 2017: Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel in metastatic castration resistant prostate cancer

ASCO 2017: The aggressive variant prostate carcinoma molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer

ASCO 2017: Identification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC

ASCO 2017: Baseline CTC subtype to predict outcomes on mCRPC patients receiving enzalutamide compared to abiraterone

ASCO 2017: Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer

ASCO 2017: Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921

ASCO 2017: Clinical outcome of metastatic castration-resistant prostate cancer patients with a post-treatment circulating tumor cell of 0 vs CTC > 0: Post hoc analysis of COU-AA-301

ASCO 2017: Association of androgen receptor gene status in plasma DNA with outcome on enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer: Exploratory results from the PREMIERE trial—On behalf of SOGUG

ASCO 2017: Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study

ASCO 2017: Comparison of biochemical recurrence free survival after radical prostatectomy triggered by grade reclassification on active surveillance, and men newly diagnosed with similar grade disease

ASCO 2017: Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza)

ASCO 2017: Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer

ASCO 2017: Efficacy of cabazitaxel rechallenged in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

ASCO 2017: Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer progressing after enzalutamide and/or

ASCO 2017: Rovalpituzumab tesirine as a therapeutic agent for Neuroendocrine Prostate Cancer

ASCO 2017: Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer: The Prostate Cancer Registry

ASCO 2017: Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer informs tumor heterogeneity

ASCO 2017: Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer from the phase 3 Prevail clinical trial

ASCO 2017: BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples

1
2
3
4
5